-
1
-
-
65249138318
-
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
-
Bibiana B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66:483-489.
-
(2009)
Arch Neurol
, vol.66
, pp. 483-489
-
-
Bibiana, B.1
Howard, T.2
Packer, A.N.3
-
2
-
-
61849150375
-
Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis
-
Broadley SA, Vanags D, Williams B, et al. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult Scler 2009; 15:329-336.
-
(2009)
Mult Scler
, vol.15
, pp. 329-336
-
-
Broadley, S.A.1
Vanags, D.2
Williams, B.3
-
3
-
-
60649090430
-
Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial
-
Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373:732-738.
-
(2009)
Lancet
, vol.373
, pp. 732-738
-
-
Goodman, A.D.1
Brown, T.R.2
Krupp, L.B.3
-
4
-
-
70450220588
-
A new drug candidate (GEMSP) for multiple sclerosis
-
Mangas A, Coveñas R, Bodet D, et al. A new drug candidate (GEMSP) for multiple sclerosis. Curr Med Chem 2009; 16:3203-3214.
-
(2009)
Curr Med Chem
, vol.16
, pp. 3203-3214
-
-
Mangas, A.1
Coveñas, R.2
Bodet, D.3
-
5
-
-
47949096771
-
Lithium prevents and ameliorates experimental autoimmune encephalomyelitis
-
De Sarno P, Axtell RC, Raman C, et al. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 2008; 181:338-345.
-
(2008)
J Immunol
, vol.181
, pp. 338-345
-
-
De Sarno, P.1
Axtell, R.C.2
Raman, C.3
-
6
-
-
70349646802
-
Delaying the onset of experimental autoimmune encephalomyelitis with the microtubule-stabilizing compounds, paclitaxel and peloruside A
-
Crume KP, O'Sullivan D, Miller JH, et al. Delaying the onset of experimental autoimmune encephalomyelitis with the microtubule-stabilizing compounds, paclitaxel and peloruside A. J Leukoc Biol 2009; 86:949-958.
-
(2009)
J Leukoc Biol
, vol.86
, pp. 949-958
-
-
Crume, K.P.1
O'Sullivan, D.2
Miller, J.H.3
-
7
-
-
64849084182
-
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-Cell receptor ligand
-
Sinha S, Subramanian S, Miller L, et al. Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-Cell receptor ligand. J Neurosci 2009; 29:3816-3823.
-
(2009)
J Neurosci
, vol.29
, pp. 3816-3823
-
-
Sinha, S.1
Subramanian, S.2
Miller, L.3
-
8
-
-
50149085078
-
An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis
-
Tafreshi1 AP, Ahmadi A, Ghaffarpur M, et al. An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis. Phytother Res 2008; 22:1083-1086.
-
(2008)
Phytother Res
, vol.22
, pp. 1083-1086
-
-
Tafreshi, A.P.1
Ahmadi, A.2
Ghaffarpur, M.3
-
9
-
-
53049089734
-
Phenytoin protects central axons in experimental autoimmune encephalomyelitis
-
Black JA, Waxman SG. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci 2008; 274:57-63.
-
(2008)
J Neurol Sci
, vol.274
, pp. 57-63
-
-
Black, J.A.1
Waxman, S.G.2
-
10
-
-
58349110928
-
The novel small molecule drug rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders
-
Hultqvist M, Nandakumar KS, Björklund U, Holmdahl R. The novel small molecule drug rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders. Ann Rheum Dis 2009; 68:130-135.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 130-135
-
-
Hultqvist, M.1
Nandakumar, K.S.2
Björklund, U.3
Holmdahl, R.4
-
11
-
-
56349083606
-
Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis
-
Paintlia AS, Paintlia MK, Singh I, Singh AK. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol 2008; 214:168-180.
-
(2008)
Exp Neurol
, vol.214
, pp. 168-180
-
-
Paintlia, A.S.1
Paintlia, M.K.2
Singh, I.3
Singh, A.K.4
-
12
-
-
46349098412
-
Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production
-
Lavrnja I, Stojkov D, Bjelobaba I, et al. Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production. Int Immunopharmacol 2008; 8:1282-1290.
-
(2008)
Int Immunopharmacol
, vol.8
, pp. 1282-1290
-
-
Lavrnja, I.1
Stojkov, D.2
Bjelobaba, I.3
-
13
-
-
41549104613
-
Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity
-
Maassen CBM, Claassen E. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine 2008; 26:2056-2057.
-
(2008)
Vaccine
, vol.26
, pp. 2056-2057
-
-
Maassen, C.B.M.1
Claassen, E.2
-
14
-
-
53049091541
-
Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encepha lomyelitis
-
Hassen GW, Feliberti J, Kesner L, et al. Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encepha lomyelitis. Brain Res 2008; 1236:206-215.
-
(2008)
Brain Res
, vol.1236
, pp. 206-215
-
-
Hassen, G.W.1
Feliberti, J.2
Kesner, L.3
-
15
-
-
58149465736
-
Comparison of the immunomodulatory effects of the plant sterol ß-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients
-
Desai F, Ramanathan M, FinkCS, et al. Comparison of the immunomodulatory effects of the plant sterol ß-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. Int Immunopharmacol 2009; 9:153-157.
-
(2009)
Int Immunopharmacol
, vol.9
, pp. 153-157
-
-
Desai, F.1
Finkcs, R.M.2
-
16
-
-
48349088568
-
Reduction of free radicals in multiple sclerosis: Effect of glatiramer acetate (Copaxone®)
-
Iarlori C, Gambi D, Lugaresi A, et al. Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone®). Mult Scler 2008; 14:739-748.
-
(2008)
Mult Scler
, vol.14
, pp. 739-748
-
-
Iarlori, C.1
Gambi, D.2
Lugaresi, A.3
-
17
-
-
68849084141
-
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
-
Jones JL, Phuah C-L, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119:2052-2061.
-
(2009)
J Clin Invest
, vol.119
, pp. 2052-2061
-
-
Jones, J.L.1
Phuah, C.-L.2
Cox, A.L.3
-
18
-
-
41849116363
-
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, Phase i Trial
-
Baror A, Calabresi PAJ, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I Trial. Ann Neurol 2008; 63:395-400.
-
(2008)
Ann Neurol
, vol.63
, pp. 395-400
-
-
Baror, A.1
Calabresi, P.A.J.2
Arnold, D.3
-
19
-
-
59349105358
-
The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relap sing-remitting multiple sclerosis
-
De Stefano N, Filippi M, Confavreux C, et al. The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relap sing-remitting multiple sclerosis. Mult Scler 2009; 15:238-243.
-
(2009)
Mult Scler
, vol.15
, pp. 238-243
-
-
De Stefano, N.1
Filippi, M.2
Confavreux, C.3
-
20
-
-
63849147004
-
Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study
-
O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009; 72:73-79.
-
(2009)
Neurology
, vol.72
, pp. 73-79
-
-
O'Connor, P.1
Comi, G.2
Montalban, X.3
-
21
-
-
48849087125
-
Repeated subcuta neous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study
-
Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcuta neous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7:796-804.
-
(2008)
Lancet Neurol
, vol.7
, pp. 796-804
-
-
Segal, B.M.1
Constantinescu, C.S.2
Raychaudhuri, A.3
-
22
-
-
50549098795
-
Intravenous immunoglobulin in relapsingremitting multiple sclerosis: A dose-finding trial
-
Fazekas F, Lublin FD, Li D, et al. Intravenous immunoglobulin in relapsingremitting multiple sclerosis: a dose-finding trial. Neurology 2008; 71:265-271.
-
(2008)
Neurology
, vol.71
, pp. 265-271
-
-
Fazekas, F.1
Lublin, F.D.2
Li, D.3
-
23
-
-
45249107267
-
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study
-
Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371:2085-2092.
-
(2008)
Lancet
, vol.371
, pp. 2085-2092
-
-
Comi, G.1
Pulizzi, A.2
Rovaris, M.3
-
24
-
-
44849103664
-
Phase 2 Trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
-
Garren H, Robinson WH MD, Krasulova E, et al. Phase 2 Trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008; 63:611-620.
-
(2008)
Ann Neurol
, vol.63
, pp. 611-620
-
-
Garren, H.1
Robinson Wh, M.D.2
Krasulova, E.3
-
25
-
-
54149116366
-
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, doubleblind, placebo-controlled phase IIb study
-
KapposL, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, doubleblind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-1472.
-
(2008)
Lancet
, vol.372
, pp. 1463-1472
-
-
Kapposl Gold, R.1
Miller, D.H.2
|